Share This Article
If You Don't Own Shares of This Tiny Biotech, Buy Now – Before Congress's $1.1 Billion Zika Vote
On Sept. 6, we showed you how a tiff between Congress and the White House had left Zika virus funding all but spent.
How would you like to put an extra $125,000 in your nest egg? You can potentially do it this year - and you'll only have to risk $20 to learn how. Click here.
Email this Article
Michael A. Robinson is a 34-year Silicon Valley veteran and one of the top technology financial analysts working today.
His work as a consultant, senior advisor and board member for Silicon Valley venture capital firms has placed him at the center of several major tech innovations including robotics used to revolutionize the auto industry... the $160 billion a year "Cloud Computing" industry... and the latest cyber military technologies.
He's also a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. It's no wonder that Silicon Valley defense publications vie for Michael's analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
His status as a leading tech analyst has garnered him rave reviews, too.
As editor of the financial newsletter American Wealth Underground, he amassed an amazing track record. The first analyst to uncover the rare earth mineral crisis, he amassed cumulative gains of 990% for his readers in just 16 months. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies - ones that have the power to sweep across the globe and change the very fabric of our lives - and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.com
Michael has an honors economics degree from the University of Missouri at Columbia. He's also a registered NRA Triple Distinguished Expert in shotgun, pistol, and rifle and one heck of a blues guitarist.
Big-cap investors were profoundly underwhelmed when the Obama administration caused Pfizer Inc. to cancel a $150 billion buyout of another massive pharma, Allergan Plc.
Like most deal-making at this level, there was a lot at stake. Allergan has a portfolio packed with name-brand drugs with long patent lives and a robust generics business. What's more, the deal would have allowed Pfizer to relocate its headquarters to the (extremely) tax-friendly Republic of Ireland and save a ton on payments to Uncle Sam.
Now, normally when a deal like this falls through, the shares take a serious pounding, but the smart money is holding its nerve. In fact, the stock is up just over 10% year to date. That says a lot.
Those investors, along with folks who buy in right now, stand to be richly rewarded in the future.